Pro-Arrhythmic Potential of Accumulated Uremic Toxins Is Mediated via Vulnerability of Action Potential

Willem B van Ham1, Carlijn M Cornelissen1, Elizaveta Polyakova1

  • 1Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

Insights

Uremic toxins (UTs) in chronic kidney disease (CKD) prolong cardiac action potential duration by reducing the IKr current and K V 11.1 protein levels. These findings suggest a pro-arrhythmogenic mechanism in dialysis patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Electrophysiology

Background:

  • Chronic kidney disease (CKD) impairs kidney filtration, leading to uremic toxin (UT) accumulation.
  • UTs are implicated in cardiac remodeling and cardiovascular deaths in dialysis patients.
  • Mechanisms linking UTs to cardiac dysfunction, particularly sudden cardiac death, are poorly understood.

Purpose of the Study:

  • To investigate the impact of clinically relevant UT concentrations on cardiac action potential repolarization.
  • To assess the effects of chronic UT exposure on cardiomyocyte electrophysiology and ion channel function.

Main Methods:

  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and HEK293 cells were chronically exposed (48h) to indoxyl sulfate, kynurenine, or kynurenic acid.
  • Electrophysiological techniques (optical mapping, manual patch-clamp) were used to measure action potential duration (APD) and IKr currents.
  • Molecular analysis of K V 11.1 (the channel responsible for IKr) protein levels was performed.

Main Results:

  • Chronic UT exposure significantly prolonged APD in hiPSC-CMs.
  • Reduced IKr current densities and decreased K V 11.1 protein levels were observed after UT exposure.
  • Treatment with an IKr activator (LUF7244) reversed UT-induced APD prolongation.

Conclusions:

  • Uremic toxins possess pro-arrhythmogenic potential by impairing cardiac repolarization.
  • A key mechanism involves the reduction of IKr current and K V 11.1 protein levels.
  • Targeting IKr current may offer a therapeutic strategy to mitigate UT-induced cardiac electrophysiological changes.

Related Concept Videos

Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
999
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Electrophysiology of Normal Cardiac Rhythm01:19

Electrophysiology of Normal Cardiac Rhythm

The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
6.6K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
50